Dr. Chen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3181 SW Sam Jackson Park Rd
# UHN73C
Portland, OR 97239Phone+1 503-494-5058
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology and Medical Oncology, 2005 - 2009- Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 2001 - 2004
Harvard Medical SchoolClass of 2001
Certifications & Licensure
HI State Medical License 2024 - 2026
CA State Medical License 2002 - 2025
OR State Medical License 2009 - 2025
WA State Medical License 2022 - 2025- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 509 citationsBrentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA)...Craig H. Moskowitz, Auayporn Nademanee, Tamas Masszi, Edward Agura, Jerzy Holowiecki
Lancet. 2015-05-09 - 155 citationsFive-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapseCraig H. Moskowitz, Jan Walewski, Auayporn Nademanee, Tamás Masszi, Edward Agura
Blood. 2018-12-20 - 36 citationsBendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas.G Ghilardi, E A Chong, J Svoboda, P Wohlfarth, S D Nasta
Annals of Oncology. 2022-09-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
